Delivery Order SPE2DB20D9331-SPE2DB23FL0K1

Award Date 12/20/22
Potential Completion Date 1/12/23
Potential Value $24K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $14,174.76, is a firm fixed-price delivery order for the supply of Kadcyla 100 mg vials, a branded oncology medication. The award is part of a larger indefinite delivery contract (IDC) between DMS Pharmaceutical Group and the DLA, valued at up to $499,999,999, which runs through...
This federal contract award, valued at $12,276.56, was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is a firm fixed-price delivery order for the supply of Kadcyla 160 mg vials, a specialized oncology medication, to support the medical needs of military healthcare facilities. DMS Pharmaceutical Group Inc. holds a larger Indefinite Delivery Contract (IDC) with the...
This federal contract award of $73,004.45 was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is a firm fixed-price delivery order for the pharmaceutical product Kadcyla 160 mg vials, with a period of performance through September 29, 2022. DMS Pharmaceutical Group holds a larger Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $42,013.48 firm fixed-price delivery order covers the supply of Kadcyla 100 mg vials, a specialized oncology medication, with a period of performance through October 9, 2024. This award is part of a larger single-award indefinite delivery contract (IDC) held by DMS Pharmaceutical Group with the DLA...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The award, a delivery order with a firm fixed price, is valued at $24,614.20 and covers the supply of the oncology drug Kadcyla (100 mg vials) with a completion date of June 23, 2023. DMS Pharmaceutical Group holds a larger $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $15,358.74, is for the supply of Kadcyla 100 mg vials, an oncology drug, with a period of performance through May 24, 2024. This order is issued under DMS Pharmaceutical Group's existing indefinite delivery contract (IDC) with the DLA, valued at up to $499,999,999,...
The U.S. Defense Logistics Agency (DLA) awarded a Firm Fixed Price Delivery Order contract worth $49,247.04 to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the delivery of 160 mg vials of the drug Kadcyla, with a completion date of January 17, 2025. This Delivery Order is part of a larger Indefinite Delivery Contract (IDC) with DMS Pharmaceutical Group valued at $499,999,999, which allows the DLA to issue firm fixed-price orders...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler located in Park Ridge, Illinois. The $15,358.74 contract is for the delivery of Kadcyla 100 mg vials, a specialized oncology medication, by January 14, 2025. This order is placed under DMS Pharmaceutical Group's existing $499,999,999 Indefinite Delivery Contract (IDC) with the DLA, which enables the agency to issue...
This is a federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $11,462.72, is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) under the SPE2DB program. The contract covers the delivery of Kadcyla 160 mg vials, a specialized oncology medication. DMS Pharmaceutical Group has a broader Indefinite Delivery Contract (IDC) with the DLA valued at...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth $20,519.60 to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the delivery of Kadcyla 160 mg vials, a specialized oncology medication, with a period of performance through November 19, 2024. This delivery order is issued under DMS Pharmaceutical Group's $499,999,999 Indefinite Delivery Contract (IDC) with the DLA, which allows the...
  • SPE2DB20D9331
    Indefinite Delivery Contract
  • SPE2DB20D9331-SPE2DB23FL0K1
    Delivery Order

This federal contract award, valued at $23,531.70, was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is a delivery order for the supply of Kadcyla 100 mg vials, an oncology medication, to support the recurring medical supply needs of military health facilities worldwide.

DMS Pharmaceutical Group holds a larger indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up to $499,999,999, which allows the agency to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items. This single-award IDC, which runs through December 31, 2025, is a key component of DMS Pharmaceutical Group's role as a crucial supplier in the federal pharmaceutical supply chain, providing both routine and critical medications to the Department of Defense healthcare system.

Generated 1/9/25, 9:08 AM